Actively Recruiting
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Led by Sun Yat-sen University · Updated on 2024-12-03
108
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
C
Chinese PLA General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
CONDITIONS
Official Title
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years
- Diagnosed with recurrent hepatocellular carcinoma (RHCC) by imaging, either first or second recurrence
- RHCC meets Milan criteria: a single lesion less than 5 cm or up to 3 tumors each 3 cm or smaller
- Recurrent HCC occurred within 1 year (early recurrence)
- Unwilling to undergo repeat hepatectomy or liver transplantation
- Well-preserved liver function: Child-Pugh class A or B and prothrombin time prolonged by 5 seconds or less
- Eastern Cooperative Oncology Group performance status score of 1 or less
- Able to understand study protocol and provide written informed consent
You will not qualify if you...
- Younger than 18 years or older than 75 years
- Primary hepatocellular carcinoma (not recurrent)
- Recurrent HCC beyond Milan criteria
- Recurrent HCC with metastasis or macrovascular tumor thrombus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General hospital
Beijing, None Selected, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou, MD
CONTACT
F
Feng Duan, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here